Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CMX157 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Placebo + Viread | PLACEBO_COMPARATOR | - |
| Viread | ACTIVE_COMPARATOR | - |
| CMX157 + Viread | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| CMX157 | DRUG | One single oral dose of CMX157 will be administered and the option of receiving a single dose of 300mg Viread will be offered 4-8 weeks after the CMX157 dose. |
| Placebo | DRUG | One single oral dose of placebo will be administered and the option of receiving a single dose of 300mg Viread will be offered 4-8 weeks after the placebo dose. |
| Viread | DRUG | One single oral dose of 300mg Viread. |
Inclusion Criteria: 1\. Males or females of non-childbearing potential, 18 to 55 years of age. Males must be able and willing to use adequate contraceptive methods throughout the study. Exclusion Criteria: 1. Currently nursing females, pregnant females, or females of child-bearing potential. 2. H...
CMX157 is an investigational small molecule drug being developed by Jazz Pharmaceuticals plc. It has been studied in a Phase 1 clinical trial in healthy adult volunteers in the United States. Its specific therapeutic indications have not been disclosed.
CMX157 is being developed by Jazz Pharmaceuticals plc, which trades on the Nasdaq under the ticker JAZZ. The company sponsored the Phase 1 study of CMX157 conducted in the United States.
CMX157 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. One Phase 1 trial has been completed, and no active trials are currently listed.
CMX157 has been evaluated in one completed Phase 1 trial, NCT01080820, titled A Safety, Tolerability and Pharmacokinetic Study of a Single Dose of CMX157 in Healthy Volunteers. The trial enrolled 36 healthy adult volunteers in the United States and was randomized, double-blind, and placebo-controlled.
The Phase 1 trial of CMX157, NCT01080820, was a randomized, double-blind, placebo-controlled study of a single dose in healthy volunteers. It enrolled 36 participants aged 18 years and older of all sexes in the United States and has been completed.